TY - JOUR
T1 - Outcome disparities among ethnic subgroups of waldenström's macroglobulinemia
T2 - A population-based study
AU - Ailawadhi, Sikander
AU - Kardosh, Adel
AU - Yang, Dongyun
AU - Cozen, Wendy
AU - Patel, Gaurav
AU - Alamgir, Mohammad A.
AU - Chanan-Khan, Asher A.
PY - 2014/7
Y1 - 2014/7
N2 - Background: Ethnic disparities in cancers are associated with variability in clinical outcomes. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of multiethnic Waldenström's macroglobulinemia (WM) patients. Methods: Adult WM patients diagnosed in 1992 or later (n = 3,175) were analyzed. Median overall survival (OS) was compared across different ethnicities stratified by year of diagnosis, registry identification, age at diagnosis, sex, and marital status. Results: African-Americans (AA) had the youngest median age at diagnosis (63 years) and Whites had the oldest (73 years) (p < 0.001). Female gender, a younger age at diagnosis, and a recent year of diagnosis were associated with an improved OS. Hispanics had the worst (5.6 years) while Whites had the best (6.8 years) median OS. A significant interaction existed between median OS, gender, and race (p = 0.007). Among males, AA had the worst (4.3 years) and Asians had the best (7.3 years) median OS. A significant interaction was also noted between median OS, age at diagnosis, and race (p = 0.033). The worst median OS was seen in Hispanics among patients aged >75 years, and in AA among those aged <65 years. Conclusions: These disparities among WM patients may be multifactorial but need to be explored systematically to better understand the disease biology and for optimal triaging of health care resources.
AB - Background: Ethnic disparities in cancers are associated with variability in clinical outcomes. We present a Surveillance Epidemiology and End Results (SEER)-based outcome analysis of multiethnic Waldenström's macroglobulinemia (WM) patients. Methods: Adult WM patients diagnosed in 1992 or later (n = 3,175) were analyzed. Median overall survival (OS) was compared across different ethnicities stratified by year of diagnosis, registry identification, age at diagnosis, sex, and marital status. Results: African-Americans (AA) had the youngest median age at diagnosis (63 years) and Whites had the oldest (73 years) (p < 0.001). Female gender, a younger age at diagnosis, and a recent year of diagnosis were associated with an improved OS. Hispanics had the worst (5.6 years) while Whites had the best (6.8 years) median OS. A significant interaction existed between median OS, gender, and race (p = 0.007). Among males, AA had the worst (4.3 years) and Asians had the best (7.3 years) median OS. A significant interaction was also noted between median OS, age at diagnosis, and race (p = 0.033). The worst median OS was seen in Hispanics among patients aged >75 years, and in AA among those aged <65 years. Conclusions: These disparities among WM patients may be multifactorial but need to be explored systematically to better understand the disease biology and for optimal triaging of health care resources.
KW - Disparity
KW - Ethnicity
KW - Surveillance Epidemiology and End Results
KW - Survival
KW - Waldenström's macroglobulinemia
UR - http://www.scopus.com/inward/record.url?scp=84901728691&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901728691&partnerID=8YFLogxK
U2 - 10.1159/000360992
DO - 10.1159/000360992
M3 - Article
C2 - 24902770
AN - SCOPUS:84901728691
SN - 0030-2414
VL - 86
SP - 253
EP - 262
JO - Oncology (Switzerland)
JF - Oncology (Switzerland)
IS - 5-6
ER -